These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 26275952)

  • 21. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
    Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
    J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FDA grants accelerated approval for ibrutinib for CLL.
    Dangi-Garimella S
    Am J Manag Care; 2014 Mar; 20(5 Spec No.):E10. PubMed ID: 25618623
    [No Abstract]   [Full Text] [Related]  

  • 23. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
    Siddiqi T; Coutre S; McKinney M; Barr PM; Rogers K; Mokatrin A; Valentino R; Szoke A; Deshpande S; Zhu A; Arango-Hisijara I; Osei-Bonsu K; Wang M; O'Brien S
    Leuk Lymphoma; 2022 Jul; 63(7):1580-1588. PubMed ID: 35227147
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ibrutinib for the treatment of mantle cell lymphoma.
    Shah N; Hutchinson C; Rule S
    Expert Rev Hematol; 2014 Oct; 7(5):521-31. PubMed ID: 25158606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.
    Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA
    JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.
    Burger JA; Tedeschi A; Barr PM; Robak T; Owen C; Ghia P; Bairey O; Hillmen P; Bartlett NL; Li J; Simpson D; Grosicki S; Devereux S; McCarthy H; Coutre S; Quach H; Gaidano G; Maslyak Z; Stevens DA; Janssens A; Offner F; Mayer J; O'Dwyer M; Hellmann A; Schuh A; Siddiqi T; Polliack A; Tam CS; Suri D; Cheng M; Clow F; Styles L; James DF; Kipps TJ;
    N Engl J Med; 2015 Dec; 373(25):2425-37. PubMed ID: 26639149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma.
    Telaraja D; Kasamon YL; Collazo JS; Leong R; Wang K; Li P; Dahmane E; Yang Y; Earp J; Grimstein M; Rodriguez LR; Theoret MR; Gormley NJ
    Clin Cancer Res; 2024 Jan; 30(1):17-22. PubMed ID: 37624619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
    Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
    Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Hillmen P; Brown JR; Eichhorst BF; Lamanna N; O'Brien SM; Qiu L; Salmi T; Hilger J; Wu K; Cohen A; Huang J; Tam CS
    Future Oncol; 2020 Apr; 16(10):517-523. PubMed ID: 32207333
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of ibrutinib in Japanese patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Shibayama H; Teshima T; Choi I; Hatake K; Sekiguchi N; Yoshinari N
    J Clin Exp Hematop; 2019; 59(4):179-186. PubMed ID: 31866619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase.
    Song Y; Zhou K; Zou D; Zhou J; Hu J; Yang H; Zhang H; Ji J; Xu W; Jin J; Lv F; Feng R; Gao S; Guo H; Zhou L; Elstrom R; Huang J; Novotny W; Wei R; Zhu J
    Clin Cancer Res; 2020 Aug; 26(16):4216-4224. PubMed ID: 32461234
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
    Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
    Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ibrutinib for treatment of chronic lymphocytic leukemia.
    Vela CM; McBride A; Jaglowski SM; Andritsos LA
    Am J Health Syst Pharm; 2016 Mar; 73(6):367-75. PubMed ID: 26953281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of acalabrutinib in patients with mantle cell lymphoma.
    Awan FT; Jurczak W
    Expert Rev Hematol; 2018 Jun; 11(6):495-502. PubMed ID: 29737219
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
    Titus-Rains KS; Brown JN; Hammond JM
    J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ibrutinib in CLL/SLL: From bench to bedside (Review).
    Zi F; Yu L; Shi Q; Tang A; Cheng J
    Oncol Rep; 2019 Dec; 42(6):2213-2227. PubMed ID: 31638169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibrutinib (Imbruvica). Relapsed chronic lymphocytic leukaemia and mantle cell lymphoma: uncertain impact on survival.
    January
    Prescrire Int; 2016 Apr; 25(170):89-92. PubMed ID: 27183765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ibrutinib for the treatment of chronic lymphocytic leukemia.
    Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
    Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
    Tran PN; O'Brien S
    Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.